Physician profile
Timothy J Gray
NPI 1699770057
$1,014.65
in general payments reported to CMS, 2019-2025
17 companies · $87.70 in 2025
The $87.70 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $181 · 2020: $480 · 2021: $118 · 2023: $15.63 · 2024: $132 · 2025: $87.70.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $235.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $235.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $302.61 | 2020-2021 | |
| Janssen Pharmaceuticals, INC | $215.16 | 2019-2020 | |
| Amarin Pharma, INC. | $96.25 | 2020 | |
| Exact Sciences Corporation | $59.99 | 2023-2024 | Cologuard Collection Kit |
| Horizon Therapeutics Plc | $55.07 | 2019 | |
| Abbvie INC. | $48.35 | 2021-2024 | |
| Glaxosmithkline, LLC. | $37.59 | 2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Bayer Healthcare Pharmaceuticals INC. | $33.37 | 2025 | |
| Phathom Pharmaceuticals, INC. | $28.45 | 2024 | Voquezna |
| Amgen INC. | $23.78 | 2021 | |
| Astellas Pharma US INC | $21.00 | 2019 | |
| Lilly USA, LLC | $20.20 | 2024 | Zepbound |
| E.R. Squibb & Sons, L.L.C. | $17.54 | 2024 | Eliquis |
| Exeltis, USA INC. | $16.74 | 2025 | Slynd |
| Merck Sharp & Dohme LLC | $14.41 | 2021 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $12.14 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $12.00 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Timothy Gray listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.